Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 478Thoracic 218Genitourinary 148Breast 106Lymphoid 92Gynecologic 69Head & Neck 50Sarcoma 44Tumor-Agnostic 26Other solid neoplasm 19Other hematologic neoplasm 13Plasma cell 6Dermatologic 5CNS 5Myeloid 3Endocrine 2Classical hematology 2Other neoplasm 1NET 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gemcitabine × Endocrine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00178698 2011-03-03

FR-WB-TT/che

The University of Texas Health Science Center, Houston

Phase 2 Unknown
36 enrolled
EndocrineGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡